Condition (MeSH)
Alstrom Syndrome
ClinicalTrials.gov lists 6 trials for Alstrom Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Alstrom Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Alstrom Syndrome trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Alstrom Syndrome trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 2 |
How many Alstrom Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 1 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Alstrom Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Liminal BioSciences Ltd. | 1 |
| Rhythm Pharmaceuticals, Inc. | 1 |
Which serious adverse events do Alstrom Syndrome trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anaemia | 1 | 1 |
| Anaphylactic reaction | 1 | 1 |
| Blindness | 1 | 1 |
| Suicidal ideation | 0 | 1 |
Which publications cover Alstrom Syndrome? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. | The lancet. Diabetes & endocrinology | 2022 | Yes |
| Comprehensive Endocrine-Metabolic Evaluation of Patients With Alström Syndrome Compared With BMI-Matched Controls. | The Journal of clinical endocrinology and metabolism | 2018 | Yes |
| Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial. | BMC endocrine disorders | 2018 | Yes |
| Respiratory manifestations in 38 patients with Alström syndrome. | Pediatric pulmonology | 2017 | Yes |
| Variable clinical course of identical twin neonates with Alström syndrome presenting coincidentally with dilated cardiomyopathy. | American journal of medical genetics. Part A | 2017 | Yes |
Showing 5 of 6 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Alström syndrome | Cases families | Worldwide | Not stated | Exact | |
| Alström syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Alström syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Alström syndrome | Cases families | Worldwide | Not stated | Exact | |
| Alström syndrome | Cases families | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Alström syndrome | 64 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Alström syndrome | 64 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.